Kidney International Reports (May 2025)
Uncovering the Link Between Kynurenic Acid Pathway and Kidney Failure
- Carolla El Chamieh,
- Sophie Liabeuf,
- Islam Amine Larabi,
- Natalia Alencar De Pinho,
- Margaux Costes-Albrespic,
- Luc Frimat,
- Céline Lange,
- Yves-Édouard Herpe,
- Jean-Charles Martin,
- Pierre Letourneau,
- Benoit Bérengère,
- Christophe Soulage,
- Stéphane Burtey,
- Jean-Claude Alvarez,
- Laetitia Koppe,
- Ziad A. Massy,
- Prs T. Hannedouche,
- B. Moulin,
- Dr A. Klein,
- Pr C. Combe,
- Dr J.P. Bourdenx,
- Dr A. Keller,
- Dr C. Delclaux,
- Dr B. Vendrely,
- Dr B. Deroure,
- Dr A. Lacraz,
- Dr T. Lobbedez,
- Dr I. Landru,
- Pr Z. Massy,
- Pr P. Lang,
- Dr X. Belenfant,
- Pr E. Thervet,
- Dr P. Urena,
- Dr M. Delahousse,
- Dr C. Vela,
- Pr M. Essig,
- Dr D. Clément,
- Dr H. Sekhri,
- Dr M. Smati,
- Dr M. Jamali,
- Dr B. Hacq,
- Dr V. Panescu,
- Dr M. Bellou,
- Pr Luc Frimat,
- Pr N. Kamar,
- Prs C. Noël et F. Glowacki,
- Dr N. Maisonneuve,
- Dr R. Azar,
- Dr M. Hoffmann,
- Pr M. Hourmant,
- Dr A. Testa,
- Dr D. Besnier,
- Pr G. Choukroun,
- Dr G. Lambrey,
- Pr S. Burtey,
- Dr G. Lebrun,
- Dr E. Magnant,
- Pr M. Laville,
- Pr D. Fouque,
- L. Juillard,
- Dr C. Chazot,
- Pr P. Zaoui,
- Dr F. Kuentz
Affiliations
- Carolla El Chamieh
- Centre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, Villejuif, France
- Sophie Liabeuf
- Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France; MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France; Sophie Liabeuf, Service de pharmacologieclinique, Département de recherche clinique, Avenue R. Laennec, Amiens, France.
- Islam Amine Larabi
- Department of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches, France; UVSQ, Université Paris-Saclay, Inserm U1018, CESP, Équipe MOODS, Montigny-le-Bretonneux, France
- Natalia Alencar De Pinho
- Centre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, Villejuif, France
- Margaux Costes-Albrespic
- Centre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, Villejuif, France
- Luc Frimat
- Nephrology Department, CHRU de Nancy, Vandoeuvre-lès-Nancy, France; Lorraine University, APEMAC, Vandoeuvre-lès-Nancy, France
- Céline Lange
- Centre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, Villejuif, France
- Yves-Édouard Herpe
- Biobanque de Picardie, CHU Amiens-Picardie, Amiens, France
- Jean-Charles Martin
- Centre de Recherche Cardiovasculaire et Nutritionnelle (C2VN), INSERM, Institut National pour la Recherche en Agriculture et l’Environnement (INRAE), BioMet, Aix-Marseille Université, Marseille, France
- Pierre Letourneau
- Departement of Nephrology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Bénite, France
- Benoit Bérengère
- Laboratoire CarMeN, INSERM U.1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre Bénite, France
- Christophe Soulage
- Laboratoire CarMeN, INSERM U.1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre Bénite, France
- Stéphane Burtey
- Aix-Marseille University, C2VN, INSERM 1263, Institut National pour la Recherche en Agriculture et l’Environnement (INRAE) 1260, Faculté SMPM, Marseille, France; Aix-Marseille University, Centre de Nephrologie et Transplantation Renale, AP-HM Hopital de la Conception, Marseille, France
- Jean-Claude Alvarez
- Department of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches, France; UVSQ, Université Paris-Saclay, Inserm U1018, CESP, Équipe MOODS, Montigny-le-Bretonneux, France
- Laetitia Koppe
- Departement of Nephrology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Bénite, France; Laboratoire CarMeN, INSERM U.1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre Bénite, France
- Ziad A. Massy
- Centre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, Villejuif, France; Association pour l’Utilisation du Rein Artificiel dans la régionparisienne (AURA), Paris, France; Ambroise Paré University Hospital, APHP, Department of Nephrology Boulogne-Billancourt/Paris, France; Correspondence: Ziad A. Massy, CESP, Université Paris-Saclay, 185 Rue Raymond Losserand, Paris, France.
- Prs T. Hannedouche
- B. Moulin
- Dr A. Klein
- Pr C. Combe
- Dr J.P. Bourdenx
- Dr A. Keller
- Dr C. Delclaux
- Dr B. Vendrely
- Dr B. Deroure
- Dr A. Lacraz
- Dr T. Lobbedez
- Dr I. Landru
- Pr Z. Massy
- Pr P. Lang
- Dr X. Belenfant
- Pr E. Thervet
- Dr P. Urena
- Dr M. Delahousse
- Dr C. Vela
- Pr M. Essig
- Dr D. Clément
- Dr H. Sekhri
- Dr M. Smati
- Dr M. Jamali
- Dr B. Hacq
- Dr V. Panescu
- Dr M. Bellou
- Pr Luc Frimat
- Pr N. Kamar
- Prs C. Noël et F. Glowacki
- Dr N. Maisonneuve
- Dr R. Azar
- Dr M. Hoffmann
- Pr M. Hourmant
- Dr A. Testa
- Dr D. Besnier
- Pr G. Choukroun
- Dr G. Lambrey
- Pr S. Burtey
- Dr G. Lebrun
- Dr E. Magnant
- Pr M. Laville
- Pr D. Fouque
- L. Juillard
- Dr C. Chazot
- Pr P. Zaoui
- Dr F. Kuentz
- DOI
- https://doi.org/10.1016/j.ekir.2025.02.024
- Journal volume & issue
-
Vol. 10,
no. 5
pp. 1404 – 1414
Abstract
Introduction: Recent studies have focused on some uremic toxins, particularly those derived from tryptophan, as potential modifiable risk factors of chronic kidney disease (CKD) progression. The kynurenine pathway is the major enzymatic pathway for sequentially catabolizing tryptophan, resulting in key metabolites including kynurenine and kynurenic acid (KA) by the aminoadipate aminotransferase. We aimed at evaluating the association of serum KA levels and KA-to-kynurenine ratio (as indicators of aminoadipate aminotransferase activity) with kidney failure. Methods: The Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) study is a prospective cohort of patients with CKD having an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m2. Baseline samples of uremic toxins were measured using a validated liquid chromatography tandem mass spectrometry technique. Cause-specific Cox models were used to estimate hazard ratios (HRs) for our outcome. The kidney gene expression of the kynurenine pathway was evaluated in 5 or 6 nephrectomy CKD mice and adenine-diet CKD mice under nephroprotective low protein diet (5% w/w). Results: Over a median follow-up period of 5 years, 608 out of the 2406 patients progressed to kidney failure. A 2-fold increase in serum KA levels and KA-to-kynurenine ratio were respectively associated with a 22% and 20%-increase in the hazard of kidney failure after multiple adjustments. In the mouse model, positive correlation was found between aminoadipate aminotransferase expression and fibrosis-related genes and kidney fibrosis. A low-protein diet was associated with a decrease in aminoadipate aminotransferase expression in the kidney as well as in inflammatory and fibrosis markers. Conclusion: Our findings suggest that the kynurenine pathway is associated with kidney failure, and that the inhibition of aminoadipate aminotransferase and the subsequent reduction of KA accumulation is a promising target to mitigate kidney disease progression.
Keywords